Ann M. Arvin
Publications
- An immunoreceptor tyrosine-based inhibition motif in varicella-zoster virus glycoprotein B regulates cell fusion and skin pathogenesis. Proc Natl Acad Sci U S A. 2013; (5): 1911-6
- Herpes simplex virus 1 tropism for human sensory ganglion neurons in the severe combined immunodeficiency mouse model of neuropathogenesis. J Virol. 2013; (5): 2791-802
- 3D reconstruction of VZV infected cell nuclei and PML nuclear cages by serial section array scanning electron microscopy and electron tomography. PLoS Pathog. 2012; (6): e1002740
- Signal transducer and activator of transcription 3 (STAT3) and survivin induction by varicella-zoster virus promote replication and skin pathogenesis. Proc Natl Acad Sci U S A. 2012; (2): 600-5
- Disruption of PML nuclear bodies is mediated by ORF61 SUMO-interacting motifs and required for varicella-zoster virus pathogenesis in skin. PLoS Pathog. 2011; (8): e1002157
- Entrapment of viral capsids in nuclear PML cages is an intrinsic antiviral host defense against varicella-zoster virus. PLoS Pathog. 2011; (2): e1001266
- Structure-function analysis of varicella-zoster virus glycoprotein H identifies domain-specific roles for fusion and skin tropism. Proc Natl Acad Sci U S A. 2011; (45): 18412-7
- Functions of the unique N-terminal region of glycoprotein E in the pathogenesis of varicella-zoster virus infection. Proc Natl Acad Sci U S A. 2010; (1): 282-7
- Varicella-zoster virus immediate-early protein 62 blocks interferon regulatory factor 3 (IRF3) phosphorylation at key serine residues: a novel mechanism of IRF3 inhibition among herpesviruses. J Virol. 2010; (18): 9240-53
- Identification of a hydrophobic domain in varicella-zoster virus ORF61 necessary for ORF61 self-interaction, viral replication, and skin pathogenesis. J Virol. 2013; (7): 4075-9
- Measles humoral and cell-mediated immunity in children aged 5-10 years after primary measles immunization administered at 6 or 9 months of age. J Infect Dis. 2013; (4): 574-82
- ORF11 Protein Interacts with the ORF9 Essential Tegument Protein in Varicella-Zoster Virus Infection. J Virol. 2013; (9): 5106-17
- Regulation of the varicella-zoster virus ORF3 promoter by cellular and viral factors. Virology. 2013; (2): 171-81
- Identification and functional characterization of the Varicella zoster virus ORF11 gene product. Virology. 2011; (1): 156-66
- Investigation of varicella-zoster virus neurotropism and neurovirulence using SCID mouse-human DRG xenografts. J Neurovirol. 2011; (6): 570-7
- Mutagenesis of varicella-zoster virus glycoprotein I (gI) identifies a cysteine residue critical for gE/gI heterodimer formation, gI structure, and virulence in skin cells. J Virol. 2011; (9): 4095-110
- Varicella zoster disease of the central nervous system: epidemiological, clinical, and laboratory features 10 years after the introduction of the varicella vaccine. J Infect Dis. 2011; (3): 316-23
- Varicella-zoster virus glycoprotein E is a critical determinant of virulence in the SCID mouse-human model of neuropathogenesis. J Virol. 2011; (1): 98-111
- Varicella-zoster virus infection triggers formation of an interleukin-1β (IL-1β)-processing inflammasome complex. J Biol Chem. 2011; (20): 17921-33
- Analysis of the functions of glycoproteins E and I and their promoters during VZV replication in vitro and in skin and T-cell xenografts in the SCID mouse model of VZV pathogenesis. Curr Top Microbiol Immunol. 2010: 129-46
- Anti-glycoprotein H antibody impairs the pathogenicity of varicella-zoster virus in skin xenografts in the SCID mouse model. J Virol. 2010; (1): 141-52
- Expression of varicella-zoster virus immediate-early regulatory protein IE63 in neurons of latently infected human sensory ganglia. J Virol. 2010; (7): 3421-30
- Impact of varicella-zoster virus on dendritic cell subsets in human skin during natural infection. J Virol. 2010; (8): 4060-72
- Varicella-zoster virus T cell tropism and the pathogenesis of skin infection. Curr Top Microbiol Immunol. 2010: 189-209
- Varicella-zoster virus neurotropism in SCID mouse-human dorsal root ganglia xenografts. Curr Top Microbiol Immunol. 2010: 255-76
- Age-related increase in the frequency of CD4(+) T cells that produce interferon-gamma in response to staphylococcal enterotoxin B during childhood. J Infect Dis. 2009; (12): 1921-7
- Deletion of the first cysteine-rich region of the varicella-zoster virus glycoprotein E ectodomain abolishes the gE and gI interaction and differentially affects cell-cell spread and viral entry. J Virol. 2009; (1): 228-40
- Mutagenesis of varicella-zoster virus glycoprotein B: putative fusion loop residues are essential for viral replication, and the furin cleavage motif contributes to pathogenesis in skin tissue in vivo. J Virol. 2009; (15): 7495-506
- One step closer to a CMV vaccine. N Engl J Med. 2009; (12): 1250-2
- Regulation of the ORF61 promoter and ORF61 functions in varicella-zoster virus replication and pathogenesis. J Virol. 2009; (15): 7560-72
- The replication cycle of varicella-zoster virus: analysis of the kinetics of viral protein expression, genome synthesis, and virion assembly at the single-cell level. J Virol. 2009; (8): 3904-18
- Varicella in the fetus and newborn. Semin Fetal Neonatal Med. 2009; (4): 209-17
- Baseline levels of influenza-specific CD4 memory T-cells affect T-cell responses to influenza vaccines. PLoS One. 2008; (7): e2574
- Development of recombinant varicella-zoster viruses expressing luciferase fusion proteins for live in vivo imaging in human skin and dorsal root ganglia xenografts. J Virol Methods. 2008; (1-2): 182-93
- Effects of interleukin-12 and interleukin-15 on measles-specific T-cell responses in vaccinated infants. Viral Immunol. 2008; (2): 163-72
- Functions of Varicella-zoster virus ORF23 capsid protein in viral replication and the pathogenesis of skin infection. J Virol. 2008; (20): 10231-46
- Functions of the ORF9-to-ORF12 gene cluster in varicella-zoster virus replication and in the pathogenesis of skin infection. J Virol. 2008; (12): 5825-34
- Humoral and cellular immunity to varicella-zoster virus: an overview. J Infect Dis. 2008: S58-60
- Immune responses to mumps vaccine in adults who were vaccinated in childhood. J Infect Dis. 2008; (12): 1669-75
- Influence of prior influenza vaccination on antibody and B-cell responses. PLoS One. 2008; (8): e2975
- Mechanisms of varicella-zoster virus neuropathogenesis in human dorsal root ganglia. J Virol. 2008; (8): 3971-83
- Phenotypic changes in influenza-specific CD8+ T cells after immunization of children and adults with influenza vaccines. J Infect Dis. 2008; (6): 803-11
- Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis. 2008; (7): 944-9
- Varicella vaccine in the United States: a decade of prevention and the way forward. J Infect Dis. 2008: S39-40
- A self-excisable infectious bacterial artificial chromosome clone of varicella-zoster virus allows analysis of the essential tegument protein encoded by ORF9. J Virol. 2007; (23): 13200-8
- Aberrant infection and persistence of varicella-zoster virus in human dorsal root ganglia in vivo in the absence of glycoprotein I. Proc Natl Acad Sci U S A. 2007; (35): 14086-91
- Age-dependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. J Infect Dis. 2007; (9): 1339-45
- Cellular and viral factors regulate the varicella-zoster virus gE promoter during viral replication. J Virol. 2007; (19): 10258-67
- Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol. 2007; (1): 215-28
- Effect of maternal herpes simplex virus (HSV) serostatus and HSV type on risk of neonatal herpes. Acta Obstet Gynecol Scand. 2007; (5): 523-9
- Genetic analysis of varicella-zoster virus ORF0 to ORF4 by use of a novel luciferase bacterial artificial chromosome system. J Virol. 2007; (17): 9024-33
- Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine. Pediatr Infect Dis J. 2007; (2): 107-15
- The ubiquitous cellular transcriptional factor USF targets the varicella-zoster virus open reading frame 10 promoter and determines virulence in human skin xenografts in SCIDhu mice in vivo. J Virol. 2007; (7): 3229-39
- A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis. 2006; (10): 1350-60
- Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol. 2006; (23): 11756-66
- Control of varicella: why is a two-dose schedule necessary? Pediatr Infect Dis J. 2006; (6): 475-6
- Essential functions of the unique N-terminal region of the varicella-zoster virus glycoprotein E ectodomain in viral replication and in the pathogenesis of skin infection. J Virol. 2006; (19): 9481-96
- Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children. Vaccine. 2006; (5): 683-90
- Inhibition of the NF-kappaB pathway by varicella-zoster virus in vitro and in human epidermal cells in vivo. J Virol. 2006; (11): 5113-24
- Investigations of the pathogenesis of Varicella zoster virus infection in the SCIDhu mouse model. Herpes. 2006; (3): 75-80
- Maternal herpes simplex virus antibody avidity and risk of neonatal herpes. Am J Obstet Gynecol. 2006; (1): 115-20
- Mutational analysis of the varicella-zoster virus ORF62/63 intergenic region. J Virol. 2006; (6): 3116-21
- New viral vaccines. Virology. 2006; (1): 240-9
- ORF66 protein kinase function is required for T-cell tropism of varicella-zoster virus in vivo. J Virol. 2006; (23): 11806-16
- Variability and gender differences in memory T cell immunity to varicella-zoster virus in healthy adults. Vaccine. 2006; (33-34): 5913-8
- Varicella-zoster virus ORF63 inhibits apoptosis of primary human neurons. J Virol. 2006; (2): 1025-31
- Varicella-zoster virus open reading frame 10 is a virulence determinant in skin cells but not in T cells in vivo. J Virol. 2006; (7): 3238-48
- Aging, immunity, and the varicella-zoster virus. N Engl J Med. 2005; (22): 2266-7
- Analysis of varicella zoster virus attenuation by evaluation of chimeric parent Oka/vaccine Oka recombinant viruses in skin xenografts in the SCIDhu mouse model. Virology. 2005; (1): 337-46
- Cell-type-dependent activation of the cellular EF-1alpha promoter by the varicella-zoster virus IE63 protein. Virology. 2005; (1): 35-42
- Chickenpox party or varicella vaccine? Adv Exp Med Biol. 2005: 11-24
- Reducing the global burden of congenital rubella syndrome: report of the World Health Organization Steering Committee On Research Related To Measles and Rubella Vaccines and Vaccination, June 2004. J Infect Dis. 2005; (11): 1890-7
- Role of the varicella-zoster virus gene product encoded by open reading frame 35 in viral replication in vitro and in differentiated human skin and T cells in vivo. J Virol. 2005; (8): 4819-27
- Strengthening the nation's influenza vaccination system: a National Vaccine Advisory Committee assessment. Am J Prev Med. 2005; (3): 221-6
- T-cell tropism and the role of ORF66 protein in pathogenesis of varicella-zoster virus infection. J Virol. 2005; (20): 12921-33
- Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model. J Virol. 2005; (5): 2651-8
- Varicella-zoster virus infection of human dorsal root ganglia in vivo. Proc Natl Acad Sci U S A. 2005; (18): 6490-5
- Viral and cellular gene transcription in fibroblasts infected with small plaque mutants of varicella-zoster virus. Antiviral Res. 2005; (2): 56-65
- Antiviral CD8 T cells in the control of primary human cytomegalovirus infection in early childhood. J Infect Dis. 2004; (9): 1619-27
- Differential requirement for cell fusion and virion formation in the pathogenesis of varicella-zoster virus infection in skin and T cells. J Virol. 2004; (23): 13293-305
- Functions of the C-terminal domain of varicella-zoster virus glycoprotein E in viral replication in vitro and skin and T-cell tropism in vivo. J Virol. 2004; (22): 12406-15
- Humoral and cell-mediated immune responses to an early 2-dose measles vaccination regimen in the United States. J Infect Dis. 2004; (1): 83-90
- Induction of cellular and humoral immunity after aerosol or subcutaneous administration of Edmonston-Zagreb measles vaccine as a primary dose to 12-month-old children. J Infect Dis. 2004; (2): 254-7
- Persistent and selective deficiency of CD4+ T cell immunity to cytomegalovirus in immunocompetent young children. J Immunol. 2004; (5): 3260-7
- T cell immunity to measles viral proteins in infants and adults after measles immunization. Viral Immunol. 2004; (2): 298-307
- T cell-dependent production of IFN-gamma by NK cells in response to influenza A virus. J Clin Invest. 2004; (12): 1812-9
- The immediate-early 63 protein of Varicella-Zoster virus: analysis of functional domains required for replication in vitro and for T-cell and skin tropism in the SCIDhu model in vivo. J Virol. 2004; (3): 1181-94
- Vaccine development to prevent cytomegalovirus disease: report from the National Vaccine Advisory Committee. Clin Infect Dis. 2004; (2): 233-9
- Varicella-zoster virus infection of human neural cells in vivo. Proc Natl Acad Sci U S A. 2004; (29): 10792-7
- Varicella-zoster virus transfer to skin by T Cells and modulation of viral replication by epidermal cell interferon-alpha. J Exp Med. 2004; (7): 917-25
- Analysis of the frequencies and of the memory T cell phenotypes of human CD8+ T cells specific for influenza A viruses. J Infect Dis. 2003; (7): 1075-84
- Construction of varicella-zoster virus recombinants from parent Oka cosmids and demonstration that ORF65 protein is dispensable for infection of human skin and T cells in the SCID-hu mouse model. J Virol. 2003; (10): 6062-5
- Differentiation of varicella-zoster virus ORF47 protein kinase and IE62 protein binding domains and their contributions to replication in human skin xenografts in the SCID-hu mouse. J Virol. 2003; (10): 5964-74
- Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination. J Infect Dis. 2003; (1): 40-52
- Long term antiviral suppression after treatment for neonatal herpes infection. Pediatr Infect Dis J. 2003; (4): 371-2
- Measles and mumps vaccination as a model to investigate the developing immune system: passive and active immunity during the first year of life. Vaccine. 2003; (24): 3398-405
- Microarray analysis of host cell gene transcription in response to varicella-zoster virus infection of human T cells and fibroblasts in vitro and SCIDhu skin xenografts in vivo. J Virol. 2003; (2): 1268-80
- Mutational analysis of open reading frames 62 and 71, encoding the varicella-zoster virus immediate-early transactivating protein, IE62, and effects on replication in vitro and in skin xenografts in the SCID-hu mouse in vivo. J Virol. 2003; (10): 5607-20
- Promoter sequences of varicella-zoster virus glycoprotein I targeted by cellular transactivating factors Sp1 and USF determine virulence in skin and T cells in SCIDhu mice in vivo. J Virol. 2003; (1): 489-98
- Requirement of varicella-zoster virus immediate-early 4 protein for viral replication. J Virol. 2003; (22): 12369-72
- Strengthening the supply of routinely recommended vaccines in the United States: recommendations from the National Vaccine Advisory Committee. JAMA. 2003; (23): 3122-8
- Varicella-zoster virus infection facilitates VZV glycoprotein E trafficking to the membrane surface of melanoma cells. J Med Virol. 2003: S56-8
- Antiviral therapy for varicella and herpes zoster. Semin Pediatr Infect Dis. 2002; (1): 12-21
- Debate: the argument against. Should all pregnant women be offered type-specific serological screening for HSV infection? Herpes. 2002; (2): 48-50
- Glycoprotein I of varicella-zoster virus is required for viral replication in skin and T cells. J Virol. 2002; (16): 8468-71
- Latent cytomegalovirus down-regulates major histocompatibility complex class II expression on myeloid progenitors. Blood. 2002; (8): 2867-73
- Memory cytotoxic T cell responses to viral tegument and regulatory proteins encoded by open reading frames 4, 10, 29, and 62 of varicella-zoster virus. Viral Immunol. 2002; (3): 507-16
- The molecular epidemiology of varicella-zoster virus: evidence for geographic segregation. J Infect Dis. 2002; (7): 888-94
- The requirement of varicella zoster virus glycoprotein E (gE) for viral replication and effects of glycoprotein I on gE in melanoma cells. Virology. 2002; (2): 176-86
- Tropism of varicella-zoster virus for human tonsillar CD4(+) T lymphocytes that express activation, memory, and skin homing markers. J Virol. 2002; (22): 11425-33
- Use of an inactivated varicella vaccine in recipients of hematopoietic-cell transplants. N Engl J Med. 2002; (1): 26-34
- Varlirix (GlaxoSmithKline). Curr Opin Investig Drugs. 2002; (7): 996-9
- Essential role played by the C-terminal domain of glycoprotein I in envelopment of varicella-zoster virus in the trans-Golgi network: interactions of glycoproteins with tegument. J Virol. 2001; (1): 323-40
- Granulysin blocks replication of varicella-zoster virus and triggers apoptosis of infected cells. Viral Immunol. 2001; (2): 125-33
- Immune evasion as a pathogenic mechanism of varicella zoster virus. Semin Immunol. 2001; (1): 27-39
- Immune evasion mechanisms of varicella-zoster virus. Arch Virol Suppl. 2001; (17): 99-107
- Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis. 2001; (7): 817-26
- Mutational analysis of the repeated open reading frames, ORFs 63 and 70 and ORFs 64 and 69, of varicella-zoster virus. J Virol. 2001; (17): 8224-39
- Natural history of neonatal herpes simplex virus infections in the acyclovir era. Pediatrics. 2001; (2): 223-9
- Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics. 2001; (2): 230-8
- Varicella vaccine--the first six years. N Engl J Med. 2001; (13): 1007-9
- Varicella vaccine: genesis, efficacy, and attenuation. Virology. 2001; (2): 153-8
- Varicella-zoster virus retains major histocompatibility complex class I proteins in the Golgi compartment of infected cells. J Virol. 2001; (10): 4878-88
- Varicella-zoster virus: molecular virology and virus-host interactions. Curr Opin Microbiol. 2001; (4): 442-9
- Frequencies of memory T cells specific for varicella-zoster virus, herpes simplex virus, and cytomegalovirus by intracellular detection of cytokine expression. J Infect Dis. 2000; (3): 859-66
- Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. J Clin Microbiol. 2000; (2): 839-45
- Glycoprotein E of varicella-zoster virus enhances cell-cell contact in polarized epithelial cells. J Virol. 2000; (23): 11377-87
- Intravenous ribavirin therapy for adenovirus pneumonia. Pediatr Pulmonol. 2000; (1): 69-73
- Measles vaccines--a positive step toward eradicating a negative strand. Nat Med. 2000; (7): 744-5
- Modulation of major histocompatibility class II protein expression by varicella-zoster virus. J Virol. 2000; (4): 1900-7
- Varicella-Zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2000; (3): 219-30
- Varicella-zoster virus gE escape mutant VZV-MSP exhibits an accelerated cell-to-cell spread phenotype in both infected cell cultures and SCID-hu mice. Virology. 2000; (2): 306-17
- Varicella-zoster virus infection of a human CD4-positive T-cell line. Virology. 2000; (2): 278-85
- Analysis of immune responses to varicella zoster viral proteins induced by DNA vaccination. Antiviral Res. 1999; (3): 179-92
- Characterization of Varicella-Zoster virus glycoprotein K (open reading frame 5) and its role in virus growth. J Virol. 1999; (5): 4197-207
- Chickenpox (varicella). Contrib Microbiol. 1999: 96-110
- Comparison of primary sensitization of naive human T cells to varicella-zoster virus peptides by dendritic cells in vitro with responses elicited in vivo by varicella vaccination. J Immunol. 1999; (1): 560-7
- Development of recombinant varicella-zoster virus vaccines. Contrib Microbiol. 1999: 193-200
- IL-12, IFN-gamma, and T cell proliferation to measles in immunized infants. J Immunol. 1999; (9): 5569-75
- Management of varicella-zoster virus infections in children. Adv Exp Med Biol. 1999: 167-74
- Nocardia farcinica pneumonia in chronic granulomatous disease. Pediatrics. 1999; (4 Pt 1): 961-4
- The epidemiology of neonatal herpes simplex virus infections in California from 1985 to 1995. J Infect Dis. 1999; (1): 199-202
- Varicella-zoster virus immune evasion. Immunol Rev. 1999: 143-56
- Analysis of the glycoproteins I and E of varicella-zoster virus (VZV) using deletional mutations of VZV cosmids. J Infect Dis. 1998: S22-6
- Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine. J Infect Dis. 1998; (6): 1701-4
- Attenuation of the vaccine Oka strain of varicella-zoster virus and role of glycoprotein C in alphaherpesvirus virulence demonstrated in the SCID-hu mouse. J Virol. 1998; (2): 965-74
- Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA. 1998; (6): 527-32
- Interleukin (IL)-10, IL-12, and interferon-gamma production in primary and memory immune responses to varicella-zoster virus. J Infect Dis. 1998; (4): 940-8
- Isolation and utilization of human dendritic cells from peripheral blood to assay an in vitro primary immune response to varicella-zoster virus peptides. J Infect Dis. 1998: S39-42
- Polymerase chain reaction and restriction fragment length polymorphism analysis of varicella-zoster virus isolates from the United States and other parts of the world. J Infect Dis. 1998: S64-6
- The ORF47 and ORF66 putative protein kinases of varicella-zoster virus determine tropism for human T cells and skin in the SCID-hu mouse. Proc Natl Acad Sci U S A. 1998; (20): 11969-74
- Varicella-zoster virus IE63, a virion component expressed during latency and acute infection, elicits humoral and cellular immunity. J Infect Dis. 1998: S43-7
- Early reconstitution of immunity and decreased severity of herpes zoster in bone marrow transplant recipients immunized with inactivated varicella vaccine. J Infect Dis. 1997; (3): 578-85
- Herpes simplex virus type 2--a persistent problem. N Engl J Med. 1997; (16): 1158-9
- Live attenuated varicella vaccine. Pediatr Ann. 1997; (6): 384-8
- Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking. J Virol. 1997; (11): 8279-88
- Recognition of the latency-associated immediate early protein IE63 of varicella-zoster virus by human memory T lymphocytes. J Immunol. 1997; (6): 2802-6
- Reliability of a history of previous varicella infection in adults. JAMA. 1997; (18): 1520-2
- The synthesis and immunogenicity of varicella-zoster virus glycoprotein E and immediate-early protein (IE62) expressed in recombinant herpes simplex virus-1. Antiviral Res. 1997; (3): 187-200
- The varicella vaccine. Curr Clin Top Infect Dis. 1997: 110-46
- Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial. Pediatr Infect Dis J. 1996; (3): 247-54
- Application of the polymerase chain reaction to the diagnosis and management of neonatal herpes simplex virus disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis. 1996; (6): 1162-7
- Immune responses to varicella-zoster virus. Infect Dis Clin North Am. 1996; (3): 529-70
- Live attenuated varicella vaccine. Annu Rev Microbiol. 1996: 59-100
- Safety and immunogenicity of one vs. two injections of Oka/Merck varicella vaccine in healthy children. Pediatr Infect Dis J. 1996; (1): 49-54
- T cell recognition and cytokine production elicited by common and type-specific glycoproteins of herpes simplex virus type 1 and type 2. J Infect Dis. 1996; (5): 899-906
- Treatment of adult varicella with sorivudine: a randomized, placebo-controlled trial. J Infect Dis. 1996; (2): 249-55
- Varicella vaccine in pregnancy. BMJ. 1996; (7059): 701-2
- Varicella-zoster virus. Clin Microbiol Rev. 1996; (3): 361-81
- Varicella-zoster virus: aspects of pathogenesis and host response to natural infection and varicella vaccine. Adv Virus Res. 1996: 263-309
- Varicella-zoster virus: overview and clinical manifestations. Semin Dermatol. 1996; (2 Suppl 1): 4-7
- Age-related differences in cell-mediated immunity to varicella-zoster virus among children and adults immunized with live attenuated varicella vaccine. J Infect Dis. 1995; (1): 13-7
- Aspects of the host response to varicella-zoster virus: a review of recent observations. Neurology. 1995; (12 Suppl 8): S36-7
- Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J Infect Dis. 1995; (1): 217-9
- Tropism of varicella-zoster virus for human CD4+ and CD8+ T lymphocytes and epidermal cells in SCID-hu mice. J Virol. 1995; (9): 5236-42
- New technology in the clinical microbiology laboratory: what you always wanted to know but were afraid to ask. J Infect Dis. 1994; (5): 1068-74
- Tumor necrosis factor, interleukin-2, and interferon-gamma in adult varicella. J Med Virol. 1994; (1): 69-71
- Analysis of the epidemiology and pathogenesis of herpes simplex virus (HSV) infections in pregnant women and infants using the HSV-2 glycoprotein G antibody assay. Infect Agents Dis. 1993; (6): 375-82
- Detection of antibodies to herpes simplex virus type 2 with a mammalian cell line expressing glycoprotein gG-2. Clin Diagn Virol. 1993; (1): 29-38
- Immunization with the immediate-early tegument protein (open reading frame 62) of varicella-zoster virus protects guinea pigs against virus challenge. J Virol. 1993; (12): 7673-6
- Investigation of the pathogenesis of varicella-zoster virus infection in guinea pigs by using polymerase chain reaction. J Infect Dis. 1993; (1): 78-83
- Multifocal leukoencephalitis caused by varicella-zoster virus in a child with leukemia: successful treatment with acyclovir. Pediatr Infect Dis J. 1993; (5): 402-6
- Cell-mediated immunity to varicella-zoster virus. J Infect Dis. 1992: S35-41
- Comparison of the Western immunoblot assay and a glycoprotein G enzyme immunoassay for detection of serum antibodies to herpes simplex virus type 2 in patients with AIDS. J Clin Microbiol. 1992; (5): 1312-4
- Herpes simplex virus infections: the genital tract and the newborn. Pediatr Rev. 1992; (3): 107-12
- Identification of women at unsuspected risk of primary infection with herpes simplex virus type 2 during pregnancy. N Engl J Med. 1992; (14): 916-20
- Immunity in strain 2 guinea-pigs inoculated with vaccinia virus recombinants expressing varicella-zoster virus glycoproteins I, IV, V or the protein product of the immediate early gene 62. J Gen Virol. 1992: 811-9
- Investigation of varicella-zoster virus infection by polymerase chain reaction in the immunocompetent host with acute varicella. J Infect Dis. 1992; (1): 188
- Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine. J Infect Dis. 1992; (5): 852-8
- Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Antimicrob Agents Chemother. 1992; (9): 1991-6
- Subclinical varicella-zoster virus viremia, herpes zoster, and T lymphocyte immunity to varicella-zoster viral antigens after bone marrow transplantation. J Infect Dis. 1992; (1): 119-26
- The management of pregnancies complicated by genital infections with herpes simplex virus. Clin Infect Dis. 1992; (6): 1031-8
- The varicella-zoster virus immediate-early protein IE62 is a major component of virus particles. J Virol. 1992; (1): 359-66
- Relationships between maternal immunity to herpes simplex virus and the risk of neonatal herpesvirus infection. Rev Infect Dis. 1991 Nov-Dec: S953-6
- A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med. 1991; (7): 444-9
- A controlled trial of acyclovir for chickenpox in normal children. N Engl J Med. 1991; (22): 1539-44
- Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype. J Immunol. 1991; (1): 257-64
- Human T cells recognize multiple epitopes of an immediate early/tegument protein (IE62) and glycoprotein I of varicella zoster virus. Viral Immunol. 1991; (3): 151-66
- Lack of transmission of the live attenuated varicella vaccine virus to immunocompromised children after immunization of their siblings. Pediatrics. 1991; (2): 166-70
- Major histocompatibility complex restriction of T-cell responses to varicella-zoster virus in guinea pigs. J Virol. 1991; (3): 1491-5
- Pharmacokinetics of acyclovir in the term human pregnancy and neonate. Am J Obstet Gynecol. 1991; (2): 569-76
- Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med. 1991; (7): 450-4
- A prospective evaluation of primary genital herpes simplex virus type 2 infections acquired during pregnancy. Pediatr Infect Dis J. 1990; (7): 499-504
- Acyclovir treatment for varicella does not lower gpI and IE-62 (p170) antibody responses to varicella-zoster virus in normal children. J Clin Microbiol. 1990; (10): 2327-30
- Herpes simplex virus infections. Pediatr Infect Dis J. 1990; (10): 765-7
- The T-lymphocyte response to varicella-zoster viral proteins. Adv Exp Med Biol. 1990: 71-81
- The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content. J Infect Dis. 1990; (5): 1049-54
- Use of polymerase chain reaction for successful identification of asymptomatic genital infection with herpes simplex virus in pregnant women at delivery. J Infect Dis. 1990; (5): 1031-5
- A concurrent epidemic of respiratory syncytial virus and echovirus 7 infections in an intensive care nursery. Pediatr Infect Dis J. 1989; (1): 24-9
- Antiviral susceptibilities of herpes simplex virus isolates from infants with recurrent mucocutaneous lesions after neonatal infection. Pediatr Infect Dis J. 1989; (4): 221-3
- Genital herpes and the pregnant woman. Curr Clin Top Infect Dis. 1989: 1-26
- Investigation of varicella-zoster virus infection of lymphocytes by in situ hybridization. J Virol. 1989; (5): 2392-5
- Neonatal antibody-dependent cellular cytotoxic antibody levels are associated with the clinical presentation of neonatal herpes simplex virus infection. J Infect Dis. 1989; (5): 770-6
- Serologic misdiagnosis of congenital infections. Pediatr Infect Dis J. 1989; (8): 542
- T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J Immunol. 1989; (2): 636-41
- Antiviral treatment of herpes simplex infection in neonates and pregnant women. J Am Acad Dermatol. 1988; (1 Pt 2): 200-3
- Changing presentation of herpes simplex virus infection in neonates. J Infect Dis. 1988; (1): 109-16
- Immunity to whole varicella-zoster virus antigen and glycoproteins I and p170: relation to the immunizing regimen of live attenuated varicella vaccine. J Infect Dis. 1988; (6): 1245-52
- Type-specific antibodies to herpes simplex virus type 2 (HSV-2) glycoprotein G in pregnant women, infants exposed to maternal HSV-2 infection at delivery, and infants with neonatal herpes. J Infect Dis. 1988; (1): 164-71
- Use of routine viral cultures at delivery to identify neonates exposed to herpes simplex virus. N Engl J Med. 1988; (14): 887-91
- Humoral and cellular immunity to varicella-zoster virus glycoprotein gpI and to a non-glycosylated protein, p170, in the strain 2 guinea-pig. J Gen Virol. 1987: 2449-54
- Pharmacokinetics of acyclovir suspension in infants and children. Antimicrob Agents Chemother. 1987; (11): 1722-6
Help
Trial Administration